C4 therapeutics reports first quarter 2025 financial results and recent business highlights

Updated cemsidomide multiple myeloma data further demonstrate compelling response rates at multiple doses and potential for best-in-class profile; 50% orr observed at the highest dose level of 100 Μ g, including one patient with a minimal residual disease negative complete response ; 40% orr achieved at the 75 Μ g dose level
CCCC Ratings Summary
CCCC Quant Ranking